-

Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST.

44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation
Date: Wednesday, January 14, 2026
Time: 11:00 - 11:25 a.m. PST
Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California

About Kashiv BioSciences:
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For more information, visit www.kashivbiosciences.com and follow us on LinkedIn.

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

Industry:

Kashiv BioSciences, LLC

Release Versions
EnglishSpanishGermanFrenchItalianDutch

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

More News From Kashiv BioSciences, LLC

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey. Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across mu...

Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company. The complex peptide product will be commercialized by Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe and the UK. The agreement covers pan-European, UK, and India markets....

Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujarat, India

AHMEDABAD, India--(BUSINESS WIRE)--Kashiv BioSciences Private Limited (“Kashiv”), a biopharmaceutical company, today announced that it has secured financing of INR 648 crore from the Union Bank of India. The proceeds will be used to expand its state-of-the-art manufacturing facility in Pipan, near Ahmedabad, Gujarat. The new single-use commercial manufacturing facility will be one of India’s largest, equipped with cutting-edge technologies to support the production of high-quality biologics and...
Back to Newsroom